Trial Profile

A Phase 3 Registration Trial of PXL065 for the Treatment of Noncirrhotic Biopsy-Proven NASH Patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pioglitazone deuterated (Primary)
Indications Non-alcoholic steatohepatitis
Focus Adverse reactions; Registrational
Sponsors Poxel

Most Recent Events

21 Sep 2021 According to a Poxel media release, results from DESTINY 1 trial should allow us to select one (or potentially two) doses that could then be studied in this confirmatory pivotal trial.
17 Nov 2019 New trial record
08 Nov 2019 According to Poxel media release, the company is planning to initiate this study in 2Q 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com